As we continue to make advancements in cancer research, we’re focused on delivering treatment options in areas of oncology with high unmet needs, including HER2-positive biliary tract cancer (BTC), as well as supporting patient communities beyond R&D. Through recent advocacy efforts, in addition to sharing new data at the upcoming ASCO 2024 Annual Meeting, we’re committed to supporting patients throughout their disease journeys.

Through our commitment to patients with unmet needs, we’re raising awareness about HER2-positive biliary tract cancer (BTC), an aggressive type of cancer often associated with a poor prognosis. As we continue to focus on those for whom we can have the greatest impact, HER2-positive cancers are one area we’re applying the science by investigating and developing innovative solutions for patients.

Our presence at SABCS 2023 marks a significant step forward for Jazz as our oncology pipeline continues to evolve to address new tumor types such as breast cancer. We’re excited to gather with leaders in the breast cancer community and share our research, including findings for our HER2-targeted bispecific antibody in HER2+ breast cancer, which reflects our continuous dedication to reshaping cancer care and addressing unmet needs. 

Recently, Mat Davis, PhD, vice president and head of data science, presented at the 2023 STAT Summit where he shared a key moment in his career when he learned the necessity of breaking down silos to fully embrace quantitative experts across the three avenues of drug development.

As World Heart Day approaches, we are reminded of people who live with complex sleep disorders and how we can adequately address their unique needs. Learn more about the importance of thinking holistically about narcolepsy and idiopathic hypersomnia patients’ health from Jazz’s Dr. Kelvin Tan and Dr. Logan Schneider of the Stanford University School of Medicine.

As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023.